Company press releases

Displaying 1 - 34 of 34 results
Released Company Title Industry Topic
15 Dec 2024
19:45 CET 		PHARMING GROUP Pharming announces public cash offer to the shareholders of Abliva AB 20103015 Pharmaceuticals Mergers, Acquiqitions, Transferts
11 Dec 2024
07:00 CET 		PHARMING GROUP Pharming announces positive topline data in pediatric clinical trial of leniolisib 20103015 Pharmaceuticals Products and services
24 Oct 2024
07:00 CEST 		PHARMING GROUP Pharming Group reports third quarter 2024 financial results and provides business update 20103015 Pharmaceuticals Commercial results
10 Oct 2024
08:00 CEST 		PHARMING GROUP Pharming Group to report third quarter 2024 financial results on October 24 20103015 Pharmaceuticals -
10 Oct 2024
07:00 CEST 		PHARMING GROUP Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation 20103015 Pharmaceuticals Products and services
26 Sep 2024
07:00 CEST 		PHARMING GROUP Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) 20103015 Pharmaceuticals Products and services
01 Aug 2024
07:00 CEST 		PHARMING GROUP Pharming Group reports second quarter and first half 2024 financial results and provides business update 20103015 Pharmaceuticals Commercial results
18 Jul 2024
08:00 CEST 		PHARMING GROUP Pharming Group to report second quarter and first half 2024 financial results on August 1 20103015 Pharmaceuticals Meetings / events
03 Jun 2024
08:00 CEST 		PHARMING GROUP Pharming Group to participate in June investor conferences 20103015 Pharmaceuticals Meetings / events
30 May 2024
22:44 CEST 		PHARMING GROUP Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union 20103015 Pharmaceuticals Products and services
21 May 2024
17:30 CEST 		PHARMING GROUP Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders 20103015 Pharmaceuticals General meeting / Board Meeting
20 May 2024
08:00 CEST 		PHARMING GROUP Pharming Group to participate in May investor conference 20103015 Pharmaceuticals Meetings / events
15 May 2024
07:00 CEST 		PHARMING GROUP Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 20103015 Pharmaceuticals Other financial transaction
08 May 2024
07:00 CEST 		PHARMING GROUP Pharming Group reports first quarter 2024 financial results and provides business update 20103015 Pharmaceuticals Commercial results
24 Apr 2024
08:00 CEST 		PHARMING GROUP Pharming Group to report first quarter 2024 financial results on May 8 20103015 Pharmaceuticals Meetings / events
24 Apr 2024
07:00 CEST 		PHARMING GROUP Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards 20103015 Pharmaceuticals Other subject
19 Apr 2024
18:43 CEST 		PHARMING GROUP Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 20103015 Pharmaceuticals Other financial transaction
18 Apr 2024
15:04 CEST 		PHARMING GROUP Pharming Group announces the placement of €100 million convertible bonds due 2029 20103015 Pharmaceuticals Other financial transaction
18 Apr 2024
08:00 CEST 		PHARMING GROUP Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 20103015 Pharmaceuticals Other financial transaction
08 Apr 2024
07:00 CEST 		PHARMING GROUP Pharming announces completion of enrollment in pediatric clinical trial of leniolisib 20103015 Pharmaceuticals Other subject
04 Apr 2024
08:30 CEST 		PHARMING GROUP Pharming Group announces the 2024 Annual General Meeting of Shareholders 20103015 Pharmaceuticals General meeting / Board Meeting
04 Apr 2024
07:00 CEST 		PHARMING GROUP Pharming Group announces the filing of its 2023 Annual Report and Form 20-F 20103015 Pharmaceuticals Commercial results
03 Apr 2024
08:00 CEST 		PHARMING GROUP Pharming Group to participate in April investor conferences 20103015 Pharmaceuticals Meetings / events
14 Mar 2024
07:00 CET 		PHARMING GROUP Pharming Group reports fourth quarter and full year 2023 financial results 20103015 Pharmaceuticals Commercial results
29 Feb 2024
08:00 CET 		PHARMING GROUP Pharming Group to report fourth quarter and full year 2023 financial results on March 14 20103015 Pharmaceuticals Meetings / events
08 Feb 2024
08:00 CET 		PHARMING GROUP Pharming Group to participate in February investor conferences 20103015 Pharmaceuticals Meetings / events
08 Jan 2024
07:00 CET 		PHARMING GROUP Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update 20103015 Pharmaceuticals Commercial results
13 Dec 2023
07:00 CET 		PHARMING GROUP Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) 20103015 Pharmaceuticals Other subject
21 Nov 2023
07:00 CET 		PHARMING GROUP Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib 20103015 Pharmaceuticals Other subject
10 Nov 2023
14:51 CET 		PHARMING GROUP Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval 20103015 Pharmaceuticals Other subject
01 Nov 2023
08:00 CET 		PHARMING GROUP Pharming Group to participate in November investor conferences 20103015 Pharmaceuticals -
26 Oct 2023
07:00 CEST 		PHARMING GROUP Pharming Group reports third quarter 2023 financial results 20103015 Pharmaceuticals Commercial results
12 Oct 2023
08:00 CEST 		PHARMING GROUP Pharming Group to report third quarter 2023 financial results on October 26 20103015 Pharmaceuticals Meetings / events
25 Sep 2023
16:00 CEST 		PHARMING GROUP Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders 20103015 Pharmaceuticals General meeting / Board Meeting